Key Facts Surrounding This News Item
- EDIT had a POWR Rating of B (Buy) coming into today.
- EDIT was 0.34% above its 10-Day Moving Average coming into today.
- EDIT was 10.59% above its 20-Day Moving Average coming into today.
- EDIT was 20.19% above its 50-Day Moving Average coming into today.
- EDIT was 32.14% above its 100-Day Moving Average coming into today.
- EDIT was 52.31% above its 200-Day Moving Average coming into today.
- EDIT had returned +5.27% year-to-date leading up to today’s news, versus a +3.47% return from the benchmark S&P 500 during the same period.
More Info About Editas Medicine, Inc. (EDIT)
Editas Medicine Inc. operates as a genome editing company. It focuses on translating its genome editing technology into a class of human therapeutics that enable precise and corrective molecular modification to treat the underlying cause of a range of diseases at the genetic level. Editas Medicine Inc. was formerly known as Gengine, Inc. and changed its name to Editas Medicine Inc. in November 2013. The company was founded in 2013 and is based in Cambridge, Massachusetts. View our full EDIT ticker page with ratings, news, and more.